Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 8 | 2019 | 1026 | 2.160 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 117 | 1.590 |
Why?
|
| Anemia, Sickle Cell | 3 | 2019 | 364 | 1.410 |
Why?
|
| Anticoagulants | 3 | 2018 | 356 | 1.320 |
Why?
|
| Daptomycin | 3 | 2014 | 11 | 1.020 |
Why?
|
| Valproic Acid | 2 | 2021 | 93 | 0.820 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 34 | 0.740 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 59 | 0.740 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 232 | 0.700 |
Why?
|
| Hypoalbuminemia | 1 | 2019 | 9 | 0.670 |
Why?
|
| Pharmacokinetics | 1 | 2019 | 14 | 0.670 |
Why?
|
| Acute Chest Syndrome | 1 | 2019 | 19 | 0.670 |
Why?
|
| Serum Albumin | 1 | 2019 | 104 | 0.650 |
Why?
|
| Central Nervous System Agents | 1 | 2019 | 37 | 0.650 |
Why?
|
| Neurotransmitter Agents | 1 | 2019 | 102 | 0.640 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2017 | 25 | 0.600 |
Why?
|
| Renal Dialysis | 2 | 2020 | 174 | 0.590 |
Why?
|
| Retrospective Studies | 11 | 2019 | 7277 | 0.590 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 71 | 0.570 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 198 | 0.560 |
Why?
|
| Vancomycin | 2 | 2018 | 60 | 0.550 |
Why?
|
| Warfarin | 2 | 2018 | 93 | 0.550 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 233 | 0.540 |
Why?
|
| Hyperphosphatemia | 1 | 2015 | 1 | 0.520 |
Why?
|
| Cohort Studies | 6 | 2019 | 2358 | 0.520 |
Why?
|
| Amphotericin B | 1 | 2015 | 26 | 0.520 |
Why?
|
| Bacteremia | 1 | 2017 | 155 | 0.510 |
Why?
|
| Antifungal Agents | 1 | 2015 | 108 | 0.490 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 131 | 0.420 |
Why?
|
| Hemarthrosis | 1 | 2012 | 3 | 0.420 |
Why?
|
| Brain Ischemia | 1 | 2018 | 665 | 0.410 |
Why?
|
| Cephalosporins | 1 | 2012 | 59 | 0.410 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2012 | 7 | 0.410 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2012 | 14 | 0.410 |
Why?
|
| Bacterial Infections | 1 | 2013 | 163 | 0.400 |
Why?
|
| Methylprednisolone | 1 | 2012 | 99 | 0.390 |
Why?
|
| Hemorrhage | 3 | 2018 | 328 | 0.380 |
Why?
|
| Humans | 21 | 2021 | 68618 | 0.360 |
Why?
|
| Enterococcus faecium | 1 | 2009 | 3 | 0.350 |
Why?
|
| Neoplasms | 2 | 2018 | 1667 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 234 | 0.350 |
Why?
|
| Endocarditis, Bacterial | 1 | 2009 | 32 | 0.340 |
Why?
|
| Treatment Outcome | 7 | 2018 | 7029 | 0.340 |
Why?
|
| Administration, Oral | 3 | 2018 | 411 | 0.310 |
Why?
|
| Female | 12 | 2019 | 38074 | 0.290 |
Why?
|
| Male | 10 | 2019 | 37321 | 0.270 |
Why?
|
| Stroke | 1 | 2018 | 2163 | 0.250 |
Why?
|
| Adult | 7 | 2019 | 21403 | 0.250 |
Why?
|
| Length of Stay | 2 | 2018 | 780 | 0.240 |
Why?
|
| Drug Interactions | 2 | 2015 | 289 | 0.220 |
Why?
|
| Aged | 6 | 2019 | 14862 | 0.210 |
Why?
|
| Middle Aged | 7 | 2019 | 21147 | 0.200 |
Why?
|
| Hirudins | 1 | 2020 | 32 | 0.190 |
Why?
|
| Liver | 2 | 2017 | 1118 | 0.180 |
Why?
|
| Hospitalization | 2 | 2017 | 978 | 0.180 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2019 | 13 | 0.170 |
Why?
|
| Iron | 1 | 2021 | 197 | 0.170 |
Why?
|
| Anticonvulsants | 1 | 2021 | 223 | 0.170 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 742 | 0.160 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2018 | 6 | 0.160 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2018 | 7 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2020 | 483 | 0.150 |
Why?
|
| Clostridium Infections | 1 | 2018 | 52 | 0.150 |
Why?
|
| Hyponatremia | 1 | 2018 | 20 | 0.150 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 29 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4848 | 0.150 |
Why?
|
| Dermatomyositis | 1 | 2017 | 31 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 89 | 0.150 |
Why?
|
| Pain, Intractable | 1 | 2017 | 28 | 0.150 |
Why?
|
| Morpholines | 1 | 2017 | 79 | 0.150 |
Why?
|
| Neuralgia | 1 | 2017 | 27 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2017 | 216 | 0.140 |
Why?
|
| Premedication | 1 | 2017 | 49 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2017 | 51 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2019 | 267 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 567 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.140 |
Why?
|
| Heparin | 1 | 2017 | 205 | 0.130 |
Why?
|
| Analgesics | 1 | 2017 | 118 | 0.130 |
Why?
|
| Thrombosis | 1 | 2017 | 218 | 0.130 |
Why?
|
| Hepatorenal Syndrome | 1 | 2015 | 16 | 0.130 |
Why?
|
| Pain Management | 1 | 2017 | 186 | 0.130 |
Why?
|
| Arterial Pressure | 1 | 2015 | 47 | 0.130 |
Why?
|
| Triazoles | 1 | 2015 | 43 | 0.130 |
Why?
|
| Patient Safety | 1 | 2017 | 202 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2015 | 107 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2018 | 335 | 0.120 |
Why?
|
| Recurrence | 1 | 2017 | 948 | 0.120 |
Why?
|
| Hematoma, Subdural | 1 | 2014 | 19 | 0.120 |
Why?
|
| beta-Alanine | 1 | 2014 | 20 | 0.110 |
Why?
|
| Comorbidity | 1 | 2018 | 1426 | 0.110 |
Why?
|
| Antithrombins | 1 | 2014 | 32 | 0.110 |
Why?
|
| Liver Function Tests | 1 | 2014 | 114 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 92 | 0.110 |
Why?
|
| Quality of Life | 1 | 2021 | 1515 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 128 | 0.110 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 156 | 0.110 |
Why?
|
| Cellulitis | 1 | 2012 | 13 | 0.110 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 23 | 0.100 |
Why?
|
| Kidney | 1 | 2017 | 945 | 0.100 |
Why?
|
| Women | 1 | 2012 | 40 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1553 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1745 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 506 | 0.090 |
Why?
|
| Decision Making | 1 | 2014 | 410 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 186 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2009 | 47 | 0.080 |
Why?
|
| Minocycline | 1 | 2009 | 61 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2009 | 226 | 0.080 |
Why?
|
| Heart Failure | 1 | 2018 | 1180 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 649 | 0.080 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.070 |
Why?
|
| South Carolina | 1 | 2012 | 2752 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2021 | 47 | 0.050 |
Why?
|
| Sodium | 1 | 2018 | 161 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2018 | 291 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 521 | 0.030 |
Why?
|
| Midodrine | 1 | 2015 | 7 | 0.030 |
Why?
|
| Octreotide | 1 | 2015 | 21 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 243 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 271 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 276 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 60 | 0.030 |
Why?
|
| Thrombelastography | 1 | 2014 | 19 | 0.030 |
Why?
|
| Dabigatran | 1 | 2014 | 35 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1851 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 301 | 0.030 |
Why?
|